Company / Operating Cash Flow
Xeris Biopharma Holdings, Inc. Operating Cash Flow History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$28.6M
FY2025
5-year range
-$95.5M / $28.6M
FY2021-FY2025
Trend
+177.4%
vs FY2024
Sector context
#70 of 216
Health Care
What the data says
At $29M, Xeris Biopharma Holdings, Inc.'s operating cash flow ranks #70 of 216 in the Health Care sector. Operating Cash Flow has increased for 3 consecutive years, from -$96M in FY2022 to $29M in FY2025.
Based on SEC 10-K filings.
$29M in FY2025.
Improved from -$47M to $29M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#70 of 216 in Health CareTop 32% of 216This company $28.6M Sector average $658.7M
▼
-95.7% below sector average
Key checks
Key Insights
- Xeris Biopharma Holdings, Inc.'s operating cash flow has grown for 3 consecutive years.
- In FY2025, operating cash flow increased 177.4% year-over-year.
- Ranks #70 out of 216 companies in the Health Care sector.
- Lowest operating cash flow in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.26 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $28.6M | +177.4% |
| FY2024 | -$37.0M | +21.4% |
| FY2023 | -$47.0M | +50.8% |
| FY2022 | -$95.5M | +0.0% |
| FY2021 | -$95.5M | -18.6% |
| FY2020 | -$80.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026